前列腺素E_1预防高危患者PCI后对比剂诱发肾病的临床研究  

Clinical Study on Contrast-induced Nephropathy with Prostaglandin E_1 Therapy in Patients with High Risk-factors Treated by PCI

作　　者：彭庆奎[1] 

机构地区：[1]枣庄市立医院心内科,山东枣庄277100

出　　处：《潍坊医学院学报》2008年第1期27-29,共3页Acta Academiae Medicinae Weifang

摘　　要：目的探讨前列腺素E1预防高危患者对比剂诱发肾病的临床效果。方法选择146例行经皮冠状动脉介入治疗(PCI),对比剂肾病发生风险评分系统评分≥11分的患者,治疗组76例给以前列腺素E1及水化治疗,对照组70例仅给以水化治疗,观察对比剂肾病的发生率。结果治疗组对比剂诱发肾病的发生率21.1%,对照组为48.5%,两组比较差异有统计学意义(P<0.05)。结论前列腺素E1能够降低PCI患者对比剂诱发肾病的发生率。Objective To study the beneficial effect of Contrast-indueed Nephropathy（CIN）combined with prostaglandin E1 therapy in patients with high risk-factors treated by PCt , Methods 146 patients treated by PCt were divided into prostaglandin E1 group（76 patients ）and control group（70 patients）. The patients in therapy group received prostaglandin E1 and water treatment,while the control group received water treatment only. We observed the SCr in both groups,and compared the results. Results The attack rate of Contrast-induced Nephropathy in prostaglandin E1 group is 21.1% , while the attaek rate of the eontrol group is 48.5% （ P 〈 0.05 ）. Conclusion Adjunctive therapy with prostaglandin E1 for patients with high risk-factors treated by PCI can decrease the attack rate of CIN.

关 键 词：对比剂诱发肾病 血肌酐 经皮介入治疗 

分 类 号：R692[医药卫生—泌尿科学]